Oppenheimer analyst Steven Lichtman maintained a Buy rating on MannKind (MNKD – Research Report) today and set a price target of $6.50. The company’s shares closed yesterday at $4.31.
According to TipRanks, Lichtman is a 5-star analyst with an average return of 11.9% and a 52.66% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as MannKind, Zimmer Biomet Holdings, and Brainsway.
In addition to Oppenheimer, MannKind also received a Buy from Leerink Partners’s Thomas Smith in a report issued on May 8. However, on the same day, RBC Capital maintained a Hold rating on MannKind (NASDAQ: MNKD).
The company has a one-year high of $5.75 and a one-year low of $3.17. Currently, MannKind has an average volume of 2.95M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MannKind (MNKD) Company Description:
MannKind Corp. is a biopharmaceutical company. It focuses on the discovery, development and, commercialization of therapeutic products for diseases, such as diabetes and cancer. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Westlake Village, CA.
Read More on MNKD:
- MannKind reports Q1 EPS 5c, consensus 3c
- MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
- MannKind: FDA grants Fast Track designation of Clofazimine Inhalation Suspension
- Is MNKD a Buy, Before Earnings?
- MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
